Clinical Trial Update: To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Abaloparatide Injection (QLG2128) for osteoporosis in postmenopausal women at high fracture risk; the study status is not yet recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Abaloparatide Injection (QLG2128) (abaloparatide)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Postmenopausal Women With Osteoporosis | Phase 3 | Status: NOT_YET_RECRUITING